The European Commission has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) that contain no mutations in the EGFR or ALK genes. The approval follows a positive recommendation from the Committee for Medicinal Products for Human Use, a branch of the European Medicines Agency. It marks the third indication for Opdivo plus Yervoy-based combinations in the EU, following…
You must be logged in to read/download the full post.
The post Opdivo-Yervoy-Chemo Combo Approved in EU for Advanced NSCLC appeared first on BioNewsFeeds.